- Diagnosis and treatment of dyslipidemia
-
Lee SH
- KMID: 2305858
- Korean J Med.
- 2008 Apr;74(4):358-362.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Combination pharmacotherapy in lipid management
-
Lee SH
- KMID: 2195067
- J Korean Med Assoc.
- 2015 Aug;58(8):745-749.
- doi: 10.5124/jkma.2015.58.8.745
Latest guidelines on lipid management recommend statins as the first-line therapy. Because limited evidence is available on cardiovascular outcomes with varying statin-nonstatin combinations, recommendation levels for these regimens have been... -
- CITED
-
- Close
- SHARE
-
- Close
- An Update on Hypertriglyceridemia-Induced Acute Pancreatitis
-
Kim HJ
- KMID: 2438042
- Korean J Med.
- 2018 Dec;93(6):518-524.
- doi: 10.3904/kjm.2018.93.6.518
Hypertriglyceridemia a major cause of acute pancreatitis, accounting for up to 10% of all cases. The pathophysiological mechanism of hypertriglyceridemia-induced acute pancreatitis (HTGP) is presumed to involve the hydrolysis of... -
- CITED
-
- Close
- SHARE
-
- Close
- Refocusing Peroxisome Proliferator Activated Receptor-alpha: A New Insight for Therapeutic Roles in Diabetes
-
Seok H, Cha BS
- KMID: 1965978
- Diabetes Metab J.
- 2013 Oct;37(5):326-332.
- doi: 10.4093/dmj.2013.37.5.326
Although glucose-lowering treatment shows some risk lowering effects in cardiovascular diseases, risks of macrovascular and microvascular complications have still remained, and development of new therapeutic strategies is needed. Recent data... -
- CITED
-
- Close
- SHARE
-
- Close
- Update on the Pharmacologic Agents for Dyslipidemia
-
Lee SH
- KMID: 2173853
- J Korean Diabetes.
- 2015 Dec;16(4):269-275.
- doi: 10.4093/jkd.2015.16.4.269
Although statins have demonstrated consistent and strong effects on cardiovascular prevention, non-statin drugs have failed to show additional clinical benefit. Consequently, statins are currently recommended as first-line therapy in dyslipidemia.... -
- CITED
-
- Close
- SHARE
-
- Close
- Hypertriglyceridemia and Cardiovascular Diseases: Revisited
-
Han SH, Nicholls S, Sakuma I, Zhao D, Koh KK
- KMID: 2344463
- Korean Circ J.
- 2016 Mar;46(2):135-144.
- doi: 10.4070/kcj.2016.46.2.135
Residual cardiovascular risk and failure of high density lipoprotein cholesterol raising treatment have refocused interest on targeting hypertriglyceridemia. Hypertriglyceridemia, triglyceride-rich lipoproteins, and remnant cholesterol have demonstrated to be important risk... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of Fenofibrate Medication on Renal Function
-
Kim S, Ko K, Park S, Lee DR, Lee J
- KMID: 2390339
- Korean J Fam Med.
- 2017 Jul;38(4):192-198.
- doi: 10.4082/kjfm.2017.38.4.192
BACKGROUND: Fibrates are widely used to treat hypertriglyceridemia, a risk factor for arteriosclerosis, but these compounds have been associated with renal dysfunction. This study aimed to investigate the effects of... -
- CITED
-
- Close
- SHARE
-
- Close
- Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy
-
Reiner Z
- KMID: 2424560
- Korean Circ J.
- 2018 Dec;48(12):1097-1119.
- doi: 10.4070/kcj.2018.0343
Although elevated serum low-density lipoprotein-cholesterol (LDL-C) is without any doubts accepted as an important risk factor for cardiovascular disease (CVD), the role of elevated triglycerides (TGs)-rich lipoproteins as an independent... -
- CITED
-
- Close
- SHARE
-
- Close
- Small Dense Low-density Lipoprotein and Cardiovascular Disease
-
Suh S, Lee MK
- KMID: 2198370
- J Lipid Atheroscler.
- 2012 Jun;1(1):1-9.
- doi: 10.12997/jla.2012.1.1.1
Cardiovascular disease (CVD) is the leading cause of death worldwide and small dense low-density lipoprotein (sdLDL) has been suggested to be a potential risk factor for cardiovascular disease (CVD). We... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety and Efficacy of Peroxisome Proliferator-Activated Receptor-alpha Agonist for Treating Cardiovascular Disease
-
Kang YR, Kwak CH, Hwang JY
- KMID: 2227034
- Korean Circ J.
- 2007 Dec;37(12):599-608.
- doi: 10.4070/kcj.2007.37.12.599
Peroxisome proliferator-activated receptor (PPAR)-alpha belongs to the nuclear family of ligand-activated transcriptional factors. The main role of PPAR-alpha is to activate the expression of the genes that are involved in... -
- CITED
-
- Close
- SHARE
-
- Close
- Postprandial Hypertriglyceridemia Following a Single High-Fat Meal in Patients with Coronary Artery Disease and Normal Subjects: The Significance of the Postprandial Hypertriglyceridemia and the Effects of Fibrate on the Postprandial Hypertriglyceridemia
-
Bae JH, Kim KB, Lee HJ, Kim KS, Kim YN, Lee IK, Huh IS, Yoon JS, Nam CW, Shin WS, Chung SJ
- KMID: 2434654
- Korean Circ J.
- 1999 Jul;29(7):680-687.
BACKGROUND AND OBJECTIVES: It has been recently reported that coronary artery disease (CAD) is more correlated with postprandial triglyceride (TG) levels than fasting TG levels. We performed this study to... -
- CITED
-
- Close
- SHARE
-
- Close
- Activation of PPARalpha Attenuates IFNgamma and IL-1beta-induced Cell Proliferation in Astrocytes: Involvement of IL-6 Independent Pathway
-
Lee JK, Seo EM, Lee SS, Park SH, Sim YB, Jung JS, Kim SM, Suh HW
- KMID: 2285401
- Korean J Physiol Pharmacol.
- 2010 Jun;14(3):185-189.
- doi: 10.4196/kjpp.2010.14.3.185
The present study demonstrates the effect of fibrates, agonists of PPARalpha on cytokines-induced proliferation in primary cultured astrocytes. Alone or combination treatment with cytokines, such as IL-1beta (10 ng/ml), IFNgamma... -
- CITED
-
- Close
- SHARE
-
- Close
- Fenofibrate Therapy and Change of Renal Function: Management, What and How?
-
Kim SH
- KMID: 2269333
- Korean J Med.
- 2014 Jun;86(6):698-701.
Fenofibrate is one of PPAR-alpha (peroxisome proliferator activated receptor alpha) agonists. Fenofibrate decreases effectively triglyceride and increases high density lipoprotein cholesterol level through the effect on lipoprotein lipase, hepatic production... -
- CITED
-
- Close
- SHARE
-
- Close
- The effect of statins on HDL-cholesterol in type 2 diabetic patients
-
Park JR, Jung JH, Moon JY, Suk JH, Kim MK, Park JH, Rhee BD
- KMID: 2305867
- Korean J Med.
- 2008 Apr;74(4):411-417.
BACKGROUND/AIMS: Statins have been a mainstay of treatment for primary and secondary prevention of coronary heart disease through their beneficial effect on lipid profile. However, their effect on the HDL... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of fenofibrate on C-reactive protein levels in hypertriglyceridemic patients
-
Lee SH, Lee KH, Choi YJ, Lee KH, Choi SH, Lee KE, Lee KJ, Kim TH, Ko HS, Kim CJ, Ryu WS
- KMID: 2305972
- Korean J Med.
- 2006 Jun;70(6):656-662.
BACKGROUND: High levels of C-reactive protein (CRP) are associated with an increased risk for cardiovascular diseases. Most reports on the effect of fibrate on CRP level have inadequate study designs... -
- CITED
-
- Close
- SHARE
-
- Close
- Fenofibrate decreases radiation sensitivity via peroxisome proliferator-activated receptor alpha-mediated superoxide dismutase induction in HeLa cells
-
Liu X, Jang SS, An Z, Song H, Kim WD, Yu JR, Park WY
- KMID: 1494299
- Radiat Oncol J.
- 2012 Jun;30(2):88-95.
- doi: 10.3857/roj.2012.30.2.88
PURPOSE: The fibrates are ligands for peroxisome proliferator-activated receptor (PPAR) alpha and used clinically as hypolipidemic drugs. The fibrates are known to cause peroxisome proliferation, enhance superoxide dismutase (SOD) expression... -
- CITED
-
- Close
- SHARE
-
- Close
- Prevalence, Treatment Pattern and Resource Use in Patients with Mixed Dyslipidemia Using Lipid Modifying Agents in Korea (PRIMULA): An Observational Study
-
Park CS, Kim HS, Lee SH, Han KH, Kim SH, Kim DI, Lee MK, Sung JD, Ahn YK, Park JH, Baek SH
- KMID: 2366137
- J Lipid Atheroscler.
- 2016 Dec;5(2):121-131.
- doi: 10.12997/jla.2016.5.2.121
OBJECTIVE: Limited information is available on the effectiveness of lipid-modifying therapy (LMT) for low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) in the Korean population. The objective... -
- CITED
-
- Close
- SHARE
-
- Close
